New Additions to Drugs.com for 2019
The following 35 drugs were added to the Drugs.com database in 2019.
Oxbryta
Nov 29, 2019 -
Xcopri
Nov 27, 2019 - Xcopri (cenobamate) is an oral, once-daily, tablet that may be used to treat partial-onset seizures in adults. The tablets can be swallowed or crushed and mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.
Adakveo
Nov 20, 2019 - Adakveo (crizanlizumab-tmca) is a P-selectin inhibitor for the prevention of vasoocclusive crises (VOCs) in patients with sickle cell disease (SCD).
Brukinsa
Nov 18, 2019 -
Vumerity
Oct 30, 2019 - Vumerity (diroximel fumarate) is an oral fumarate for the treatment of relapsing forms of multiple sclerosis (MS).
Trikafta
Oct 23, 2019 - Trikafta is an oral combination medication that contains elexacaftor, ivacaftor, and tezacaftor, which may be used to treat adults and children aged 2 years and older with cystic fibrosis who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or another mutation that is responsive to treatment with Trikafta.
Reyvow
Oct 11, 2019 - Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.
Aklief
Oct 8, 2019 - Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older.
Rybelsus
Sep 20, 2019 - Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus.
Ibsrela
Sep 13, 2019 - Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
Inrebic
Sep 9, 2019 - Inrebic (fedratinib) is a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.
Nourianz
Sep 1, 2019 - Nourianz (istradefylline) is an adenosine A2A receptor antagonist indicated for use as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “OFF” episodes.
Rozlytrek
Sep 1, 2019 -
Rinvoq
Aug 22, 2019 -
Turalio
Aug 19, 2019 - Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.
Nubeqa
Aug 5, 2019 -
Baqsimi
Jul 24, 2019 - Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of
severe hypoglycemia in diabetes patients ages 4 years and older.
Xpovio
Jul 9, 2019 - Xpovio (selinexor) is a nuclear export inhibitor for the treatment of patients adult patients with relapsed or refractory multiple myeloma.
Vyleesi
Jul 8, 2019 - Vyleesi (bremelanotide) is a melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Slynd
Jun 11, 2019 - Slynd (drospirenone) is a progestin oral contraceptive for birth control.
Piqray
May 30, 2019 - Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the
treatment of postmenopausal women, and men, with HR positive, HER2-negative,
PIK3CA-mutated breast cancer.
Nayzilam
May 20, 2019 - Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters.
Qternmet XR
May 7, 2019 - Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Skyrizi
Apr 29, 2019 -
Balversa
Apr 28, 2019 - Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.
Duobrii
Apr 27, 2019 - Duobrii (halobetasol propionate and tazarotene) is a corticosteroid and retinoid combination indicated for the topical treatment of plaque psoriasis.
Evenity
Apr 16, 2019 - Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Dovato
Apr 15, 2019 - Dovato (dolutegravir and lamivudine) is a once-daily, single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and lamivudine (Epivir) indicated for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older.
Duaklir Pressair
Apr 15, 2019 - Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD.
Mavenclad
Apr 14, 2019 - Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of
relapsing forms of multiple sclerosis (MS).
Mayzent
Apr 1, 2019 - Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of secondary progressive multiple sclerosis.
Sunosi
Mar 28, 2019 - Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Zulresso
Mar 28, 2019 - Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA)
receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).
Spravato
Mar 6, 2019 - Spravato (esketamine) is a prescription nasal spray indicated for use in adults with treatment-resistant depression, and major depressive disorder (MDD) with acute suicidal ideation or behavior.
Jeuveau
Feb 13, 2019 - Jeuveau (prabotulinumtoxinA) is a botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines.